The initial result wasn’t what Eli Lilly & Co. and its development partner Avid Radiopharmaceuticals Inc. wanted for their potential Alzheimer’s diagnostic agent Amyvid (florbetapir) going into the panel meeting.
The Food & Drug Administration’s Peripheral & Central Nervous System Drugs Advisory Committee voted 13-3 against immediate approval of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?